-+ 0.00%
-+ 0.00%
-+ 0.00%

Oramed Pharmaceuticals To Acquire 49.99% Stake In 49.99%, To Integrate Proprietary Protein Oral Delivery Technology; Lifeward To Issue $10M Convertible Notes, Oramed To Invest $9M Of Convertible Notes

Benzinga·01/13/2026 13:04:12
Listen to the news

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed's proprietary Protein Oral Drug POD™ delivery technology and Oramed obtaining 49.9% beneficial ownership interest in Lifeward upon the satisfaction of certain terms and conditions. In addition, Lifeward to issue $10 million in senior secured convertible notes in a private placement, of which Oramed to invest $9 million, and an additional milestone-based $10 million senior secured convertible note, of which Oramed will invest $9 million, each with 100% warrant coverage. The transaction allows Oramed to significantly increase its ownership stake in Lifeward upon full conversion of the notes and exercises of the warrants.